FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200301281> ?p ?o ?g. }

• W4200301281 endingPage "86" @default.
• W4200301281 startingPage "70" @default.
• W4200301281 abstract "Introduction . In recent years, interest in the use of radical prostatectomy (RPE) as one of the components of a multimodal approach in patients with lymphogenous disseminated and metastatic prostate cancer (PCa) has grown significantly. At the same time, the dearth of large randomized trials does not make it possible to use this technique in wide clinical practice outside of clinical trials. Purpose of the study . To evaluate the effectiveness of multimodal therapy using combined chemo-hormonal, surgical and radiation therapy in patients with primary oligometastatic hormone-sensitive PCa. Material and methods . The study included 48 patients with primary oligometastatic prostate cancer who received combination treatment within the internal one-research-center protocol. At the first stage, all patients underwent combined drug therapy with docetaxel (75 mg/m 2 intravenously every 3 weeks for 6 courses) and degarelix. Patients who had a decrease in PSA level ≤ 2 ng/ml and registered stabilization of the disease according to radiological examination were treated surgically through RPE with extended pelvic and retroperitoneal lymph node dissection. Radiation therapy was performed only in patients with the presence of bone lesions at a dose of 50-70 Gy to the location of bone metastases in the stage 3 plan of combined multimodal therapy. Results . PCa biochemical relapse was verified in 27 (56.3%) patients during the median follow-up of 10 months. The average time to PSA increase was 9.0 ± 5.7 months (from 1 to 24 months), median — 7 months, Six-month PSA relapse-free survival (PSA-RFS) was 61.2 ± 7.5%; 1-year PSA-RFS — 38.0 ± 8.6%. The average duration before the initiation of hormonal therapy was 12 ± 6.1 months (from 3 to 27 months), median: 10 months. Six-month survival before the drug administration was 72.6 ± 6.8%; twelve-month survival: 40.9 ± 8.7%. About 40% of patients with oligometastatic PCa had no signs of progression and did not receive any other drug therapy for 12 months after completion of protocol treatment. Conclusions . Analysis of the study results demonstrates satisfactory oncological outcomes of the studied treatment option in patients with newly diagnosed oligometastatic hormone-sensitive PCa, as well as a low likelihood of side effects and complications. Nevertheless, it is necessary to continue conducting larger and more structured randomized trials to determine the possibility of applying this therapeutic approach in clinical practice." @default.
• W4200301281 created "2021-12-31" @default.
• W4200301281 creator A5019977496 @default.
• W4200301281 creator A5025938930 @default.
• W4200301281 creator A5045547815 @default.
• W4200301281 date "2021-12-23" @default.
• W4200301281 modified "2023-09-23" @default.
• W4200301281 title "Multimodal therapy for oligometastatic prostate cancer: results from a single-centre study" @default.
• W4200301281 cites W1496368376 @default.
• W4200301281 cites W2142466432 @default.
• W4200301281 cites W2147509995 @default.
• W4200301281 cites W2514775981 @default.
• W4200301281 cites W2516994642 @default.
• W4200301281 cites W2629135149 @default.
• W4200301281 cites W2762652685 @default.
• W4200301281 cites W2783947396 @default.
• W4200301281 cites W2787804990 @default.
• W4200301281 cites W2788160989 @default.
• W4200301281 cites W2806525014 @default.
• W4200301281 cites W2894350218 @default.
• W4200301281 cites W2921268519 @default.
• W4200301281 cites W2940058107 @default.
• W4200301281 cites W2943111805 @default.
• W4200301281 cites W2947893479 @default.
• W4200301281 cites W3039369851 @default.
• W4200301281 cites W3128646645 @default.
• W4200301281 doi "https://doi.org/10.21886/2308-6424-2021-9-4-70-86" @default.
• W4200301281 hasPublicationYear "2021" @default.
• W4200301281 type Work @default.
• W4200301281 citedByCount "0" @default.
• W4200301281 crossrefType "journal-article" @default.
• W4200301281 hasAuthorship W4200301281A5019977496 @default.
• W4200301281 hasAuthorship W4200301281A5025938930 @default.
• W4200301281 hasAuthorship W4200301281A5045547815 @default.
• W4200301281 hasBestOaLocation W42003012811 @default.
• W4200301281 hasConcept C121608353 @default.
• W4200301281 hasConcept C126322002 @default.
• W4200301281 hasConcept C126894567 @default.
• W4200301281 hasConcept C141071460 @default.
• W4200301281 hasConcept C146357865 @default.
• W4200301281 hasConcept C151730666 @default.
• W4200301281 hasConcept C168563851 @default.
• W4200301281 hasConcept C2775862295 @default.
• W4200301281 hasConcept C2776235491 @default.
• W4200301281 hasConcept C2778311097 @default.
• W4200301281 hasConcept C2779466945 @default.
• W4200301281 hasConcept C2780192828 @default.
• W4200301281 hasConcept C2780849966 @default.
• W4200301281 hasConcept C2781190966 @default.
• W4200301281 hasConcept C4441509 @default.
• W4200301281 hasConcept C509974204 @default.
• W4200301281 hasConcept C71924100 @default.
• W4200301281 hasConcept C86803240 @default.
• W4200301281 hasConceptScore W4200301281C121608353 @default.
• W4200301281 hasConceptScore W4200301281C126322002 @default.
• W4200301281 hasConceptScore W4200301281C126894567 @default.
• W4200301281 hasConceptScore W4200301281C141071460 @default.
• W4200301281 hasConceptScore W4200301281C146357865 @default.
• W4200301281 hasConceptScore W4200301281C151730666 @default.
• W4200301281 hasConceptScore W4200301281C168563851 @default.
• W4200301281 hasConceptScore W4200301281C2775862295 @default.
• W4200301281 hasConceptScore W4200301281C2776235491 @default.
• W4200301281 hasConceptScore W4200301281C2778311097 @default.
• W4200301281 hasConceptScore W4200301281C2779466945 @default.
• W4200301281 hasConceptScore W4200301281C2780192828 @default.
• W4200301281 hasConceptScore W4200301281C2780849966 @default.
• W4200301281 hasConceptScore W4200301281C2781190966 @default.
• W4200301281 hasConceptScore W4200301281C4441509 @default.
• W4200301281 hasConceptScore W4200301281C509974204 @default.
• W4200301281 hasConceptScore W4200301281C71924100 @default.
• W4200301281 hasConceptScore W4200301281C86803240 @default.
• W4200301281 hasIssue "4" @default.
• W4200301281 hasLocation W42003012811 @default.
• W4200301281 hasLocation W42003012812 @default.
• W4200301281 hasOpenAccess W4200301281 @default.
• W4200301281 hasPrimaryLocation W42003012811 @default.
• W4200301281 hasRelatedWork W11945040 @default.
• W4200301281 hasRelatedWork W14767499 @default.
• W4200301281 hasRelatedWork W15075455 @default.
• W4200301281 hasRelatedWork W16736519 @default.
• W4200301281 hasRelatedWork W3528779 @default.
• W4200301281 hasRelatedWork W5537359 @default.
• W4200301281 hasRelatedWork W7939232 @default.
• W4200301281 hasRelatedWork W9085563 @default.
• W4200301281 hasRelatedWork W9722579 @default.
• W4200301281 hasRelatedWork W9738371 @default.
• W4200301281 hasVolume "9" @default.
• W4200301281 isParatext "false" @default.
• W4200301281 isRetracted "false" @default.
• W4200301281 workType "article" @default.